ERBB2 and gastroesophageal junction adenocarcinoma: Therefore, our response to CQ is as follows: “There is strong evidence to recommend evaluation of the expression statuses of HER2, PD-L1 CPS, MSI, and claudin 18.2 prior to first-line chemotherapy in patients with unresectable esophagogastric junction adenocarcinoma.”